+86-400-890-9989
Product Catalog
> Receptor Tyrosine Kinase Receptor Tyrosine Kinase
Sino Biological offers a comprehensive set of tools for research on receptor tyrosine kinases (RTKs), including recombinant proteins, antibodies (rabbit mAbs, mouse mAbs, rabbit pAbs), ELISA kits, and ORF cDNA clones. Receptor tyrosine kinases are a diverse group of transmembrane proteins that act as receptors for cytokines, growth factors, hormones and other signaling molecules. Receptor tyrosine kinases are expressed in many cell types and play important roles in a wide variety of cellular processes, including growth, differentiation and angiogenesis.
| Product / Species | Human | Mouse | Rat | Dog | Cynomolgus |
| Recombinant Proteins | 66 | 29 | 3 | 1 | 2 |
| Antibodies | 76 | 8 | - | - | - |
| ELISA Kit | 8 | - | - | - | - |
| ORF cDNA Clones | 36 | 23 | 4 | - | 1 |
Receptor Tyrosine Kinase Products
Please click the molecular formulas to find products that you are interested.
* Being developed. Tell us your requirement so that the products of interest be placed on the priority list.
|
||
|
||
Receptor Tyrosine Kinase Background
Receptor tyrosine kinases are a diverse group of transmembrane proteins that act as receptors for cytokines, growth factors, hormones and other signaling molecules. Receptor tyrosine kinases are expressed in many cell types and play important roles in a wide variety of cellular processes, including growth, differentiation and angiogenesis. Upon ligands binding, receptor tyrosine kinases undergo dimerization and autophosphorylation of specific intracellular tyrosine sites. This leads to establishment of docking sites for Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain containing proteins, followed by substrate phosphorylation and signal initiation. Other proteins that interact with the activated receptor tyrosine kinase act as adaptor proteins and have no intrinsic enzymatic activity of their own.
Receptor tyrosine kinases have been shown to play a critical role in the development and progression of many types of cancer. Inhibition of receptor tyrosine kinases seems to be effective strategies in cancer therapy. The EGFR inhibitors Erlotinib, Gefitinib, and Cetuximab have undergone extensive clinical testing and have established clinical activity in non small cell lung cancer (NSCLS) and other types of solid tumors.
Receptor Tyrosine Kinase Related Studies
- Pawson T. (1995) Protein modules and signalling networks. Nature 373(6515):573–580.
- Zwick E, et al. (2001). Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr. Relat. Cancer. 8(3):161-173.
- Haluska P, et al. (2001) Receptor tyrosine kinase inhibitors. Curr Opin Investig Drugs. 2(2):280-6.
- Sharma PS, et al. (2009) Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des. 15(7):758-76.
